Comprehensive Review on Plant-Derived Antifungals: Nigella sativa and Catharanthus roseus Against Opportunistic Candida Infections
Fungal infections caused by Candida species represent a critical global healthcare challenge due to the rising prevalence of immunocompromised host conditions and increasing resistance to conventional antifungal agents. Synthetic therapies—including azoles, echinocandins, and polyenes—are frequently limited by host toxicity, adverse drug interactions, high costs, and the rapid emergence of multidrug-resistant strains like Candida auris. Consequently, plant-based secondary metabolites have gained attention as alternative or synergistic therapeutic agents. This review provides a comprehensive synthesis of the pathogenic burden of candidiasis, mechanisms of current antifungal classes, and the therapeutic efficacy of Nigella sativa Linn. and Catharanthus roseus Linn. Active constituents such as thymoquinone (N. sativa) and indole alkaloids (C. roseus) demonstrate distinct multi-target antimicrobial mechanisms. Pharmacological evaluation highlights the superior antifungal potency of N. sativa extracts over C. roseus against various clinical Candida strains. Furthermore, current research gaps, standardization challenges, and future clinical integration strategies are critically evaluated.
Authors
- Rajesh Asija
- Richa Agarwal
- Najrana
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24414657
- Primary Topic
- Nigella sativa pharmacological applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00